BioSpace News Archive

Vertex and Verve announced they had entered an exclusive four-year research partnership to discover and nurture a gene editing therapy for yet-undisclosed liver disease.

A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.

Frontera Therapeutics closed on a Series B funding round worth $160 million and announced an IND approval by the FDA for rare genetic retinal disease

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of the two most common forms of chronic inducible urticaria (CIndU).

Daxor Corporation announces today it has entered into an industry partnership with MedAxiom.

Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointments of Vikram Arora, Ph.D., DABT, as Vice President of Non-Clinical Development; Erin O’Neil, M.D., as Vice President of Clinical Development; and Sarah Tuller, J.D., RAC, as Vice President of Regulatory Affairs and Medical Writing.

180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously-announced registered direct offering to a single healthcare-focused U.S. institutional investor of 6,132,076 shares of the Company’s common stock.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (the “Company” or “ReWalk”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received Israeli court approval to repurchase up to $8 million of its Ordinary Shares, par value NIS 0.25 per share.

Horizon Therapeutics plc Announces Inaugural #RAREis Global Advocate Grant Recipients.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022).